Two-Pronged attack tested for Tough-to-Treat breast cancer
NCT ID NCT03025035
Summary
This study tested a combination of two drugs, pembrolizumab and olaparib, for people with advanced breast cancer linked to specific genetic changes (BRCA or HDR defects). The goal was to see if using an immunotherapy drug together with a targeted therapy could shrink tumors and control the cancer. It involved 14 participants whose cancer had progressed after prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.